JP2023531008A5 - - Google Patents
Info
- Publication number
- JP2023531008A5 JP2023531008A5 JP2022578713A JP2022578713A JP2023531008A5 JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5 JP 2022578713 A JP2022578713 A JP 2022578713A JP 2022578713 A JP2022578713 A JP 2022578713A JP 2023531008 A5 JP2023531008 A5 JP 2023531008A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- abnormality
- pharmaceutically acceptable
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20181221.1 | 2020-06-19 | ||
| EP20181221 | 2020-06-19 | ||
| EP21164097 | 2021-03-22 | ||
| EP21164097.4 | 2021-03-22 | ||
| PCT/EP2021/066695 WO2021255279A1 (en) | 2020-06-19 | 2021-06-18 | D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531008A JP2023531008A (ja) | 2023-07-20 |
| JP2023531008A5 true JP2023531008A5 (cg-RX-API-DMAC7.html) | 2024-06-25 |
Family
ID=76532220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578713A Pending JP2023531008A (ja) | 2020-06-19 | 2021-06-18 | Nlrp3インフラマソーム経路を調節するジヒドロオキサゾール及びチオ尿素または尿素誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12624010B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4168395B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023531008A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230028425A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768754B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021291065B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022025612A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178361A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299084A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014709A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021255279A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202212873B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| JP2025502732A (ja) * | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1270565T3 (da) | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| GB2561540A (en) | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| US11370763B2 (en) | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| ES2927851T3 (es) | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CR20200588A (es) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| WO2020157069A1 (en) | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| JP2022547882A (ja) | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Nlrp3阻害剤 |
-
2021
- 2021-06-18 US US18/010,032 patent/US12624010B2/en active Active
- 2021-06-18 IL IL299084A patent/IL299084A/en unknown
- 2021-06-18 WO PCT/EP2021/066695 patent/WO2021255279A1/en not_active Ceased
- 2021-06-18 MX MX2022014709A patent/MX2022014709A/es unknown
- 2021-06-18 CN CN202180043283.6A patent/CN115768754B/zh active Active
- 2021-06-18 AU AU2021291065A patent/AU2021291065B2/en active Active
- 2021-06-18 EP EP21733822.7A patent/EP4168395B1/en active Active
- 2021-06-18 BR BR112022025612A patent/BR112022025612A2/pt unknown
- 2021-06-18 KR KR1020237002124A patent/KR20230028425A/ko active Pending
- 2021-06-18 JP JP2022578713A patent/JP2023531008A/ja active Pending
- 2021-06-18 CA CA3178361A patent/CA3178361A1/en active Pending
-
2022
- 2022-11-25 ZA ZA2022/12873A patent/ZA202212873B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017447A5 (cg-RX-API-DMAC7.html) | ||
| JP2021530536A5 (cg-RX-API-DMAC7.html) | ||
| CN105121430B (zh) | 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂 | |
| HRP20211225T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| TWI758300B (zh) | 免疫調節劑化合物 | |
| JP2022530985A5 (cg-RX-API-DMAC7.html) | ||
| JP7843705B2 (ja) | Nlrp3モジュレーターとしてのスルホンイミドアミド化合物 | |
| JP2023508142A5 (cg-RX-API-DMAC7.html) | ||
| JP2021523200A5 (cg-RX-API-DMAC7.html) | ||
| JP2020529405A5 (cg-RX-API-DMAC7.html) | ||
| JP2025524640A (ja) | Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 | |
| CA2777290C (en) | Process for the preparation of f-series prostaglandins | |
| EP4482823A1 (en) | Di-cyclopropyl based il-17a modulators and uses thereof | |
| CN114981262B (zh) | 杂芳基化合物及其制备方法和用途 | |
| JP2023532298A (ja) | 化合物、組成物及び方法 | |
| CN115768754B (zh) | 调节nlrp3炎症小体通路的二氢噁唑和硫脲或脲衍生物 | |
| HRP20240896T1 (hr) | Derivati sulfoniluree i njihova upotreba | |
| WO2019167982A1 (ja) | 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途 | |
| JP2017525684A5 (cg-RX-API-DMAC7.html) | ||
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| TW202502756A (zh) | 作為il17的調節劑的新穎化合物 | |
| CN116836176B (zh) | 青蒿素类化合物、其制备方法和应用 | |
| EP4452972A1 (en) | Dihydro-oxazol derivative compounds | |
| JP2026065124A (ja) | アミノ酸誘導体の結晶形及びその製造方法 | |
| RU2838028C2 (ru) | Соединения для лечения pd-l1 заболеваний |